FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs

The FDA has issued a warning about a rare but serious eye condition, non-arteritic anterior ischemic optic neuropathy (NAION), linked to GLP-1 drugs, which are commonly prescribed for diabetes and weight loss. This condition, often called an "eye stroke," can cause sudden vision loss, prompting the FDA to mandate that pharmaceutical companies include this risk in patient and provider warnings. This move underscores the importance of monitoring side effects for widely used medications, highlighting the need for ongoing vigilance in drug safety.